🇺🇸 FDA
Pipeline program

hydrocortisone (modified release), oral tablet 20 and 5 mg

DC 06/02

Phase 3 small_molecule completed

Quick answer

hydrocortisone (modified release), oral tablet 20 and 5 mg for Adrenal Insufficiency is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Adrenal Insufficiency
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials